Brickell Biotech – Consensus Indicates Potential 370.1% Upside

Broker Ratings

Brickell Biotech found using ticker (BBI) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 6 and 5 with a mean TP of 5.5. With the stocks previous close at 1.17 this would imply there is a potential upside of 370.1%. The day 50 moving average is 0.79 while the 200 day moving average is 0.8. The company has a market capitalisation of $60m. Find out more information at:

Brickell Biotech, a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company’s lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech has a collaboration agreement with AnGes for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index